Whereas flavan-3-ols alleviated NAFLD not by direct FXR agonism but through inhibiting SHP and upregulating CYP7A1 and CYP8B1 in the liver, while suppressing SHP and TGR5 in the intestine (Vauzour et al., 2018). Here, NR0B2 is linked to metabolic dysfunction-associated steatotic liver disease.